Overview

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Status:
Completed

Trial end date:
2012-03-02

Target enrollment:

Participant gender:

Summary

The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Evolocumab
Ezetimibe